Table 3.

Comparison of changes in cognitive and functional outcomes between the cilostazol and placebo groups

Test	Cilostazol (n = 18)			Control (n = 18)			p
	Baseline	12 weeks	24 weeks	Baseline	12 weeks	24 weeks	Group	Time	Interaction
MMSE	15.11 ± 3.61	16.67 ± 4.04	15.39 ± 3.94	15.44 ± 3.96	15.83 ± 4.84	16.22 ± 4.91	0.93	0.09	0.15
ADAS-cog	29.28 ± 8.79	26.33 ± 6.75	25.78 ± 8.19	27.78 ± 7.89	24.83 ± 7.67	24.78 ± 7.41	0.59	< 0.001*	0.93
ADCS-ADL	50.17 ± 11.61	48.00 ± 13.14	46.33 ± 15.88	53.56 ± 14.86	49.33 ± 17.38	51.17 ± 16.53	0.50	0.07	0.82
CDR (sum)	5.11 ± 2.30	5.42 ± 2.05	5.44 ± 2.49	4.72 ± 1.56	5.28 ± 2.18	5.33 ± 2.88	0.77	0.07	0.79

Data are given as mean ± S.D. Repeated measures analysis of variance (ANOVA) was used to compare differences

MMSE = Mini-Mental State Exam; ADAS-cog = the cognitive portion of the Alzheimer’s Disease Assessment Scale; ADCS-ADL = the Alzheimer’s Disease Cooperative Study-Activities of Daily Living; CDR-SB = the sum of the boxes of the Clinical Dementia Rating Scale

*Significance level was set as p equal to 0.05 or less